Yanxin Tian

机构：University of California, Los Angeles

发表论文 7 篇 · 总被引 199 次 · h-index 6

代表论文

• Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy (2024 · Molecular Therapy · 被引 65)
• Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies (2025 · Nature Communications · 被引 52)
• Biological functions and therapeutic applications of human mucosal-associated invariant T cells (2025 · Journal of Biomedical Science · 被引 24)
• Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity (2025 · Journal of Hematology & Oncology · 被引 20)
• Allogeneic stem cell-engineered EGFRvIII-specific CAR-NKT cells for treating glioblastoma with enhanced efficacy and safety (2025 · Molecular Therapy · 被引 18)
• Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells (2025 · Cell Reports Medicine · 被引 15)